Evan J. McGillin advises clients on corporate matters with a focus on equity and debt financings, mergers and acquisitions (M&A), corporate governance, and securities laws. A member of the firm’s emerging companies and venture capital practice, Evan represents established and emerging growth companies and the investors that finance them in a variety of industries including technology, fintech, digital health, and life sciences.
Evan regularly represents emerging growth companies throughout their entire life cycle, including formation, equity and debt financings, restructurings, M&A, and other strategic transactions. Additionally, Evan advises founders, senior management, and boards of directors on corporate governance, securities law compliance, equity and incentive structures, commercial agreements, and intellectual property matters.
Evan also represents angel, private equity, venture capital, strategic, and sovereign wealth fund investors in connection with financing transactions and M&A.
Represented a gene therapy CDMO in multiple convertible debt and equity financings, raising more than $240 million in the aggregate
Represented Slide, an artificial intelligence and insurtech startup, in its $100 million Series A financing
Represented a content management and digital experience software company in its $80 million Series C financing
Represented Particle Health Inc. in its $12 million Series A financing led by Menlo Ventures
Represented a provider of a first-in-class epilepsy treatment in its $12 million convertible note financing
Represented a medical device manufacturer in its recapitalization and $15 million Series B financing
Represented the lead investors in a biopharmaceutical company’s $45 million Series C financing
Represented a leading provider of loss-control software for property and casualty insurers in its Series A-1 financing
Represented a US professional sports league in various equity and convertible debt financings
Represented a high-performance computing startup in its spinout from a Fortune 100 technology company and subsequent debt and equity financings, raising more than $50 million
Strategic Mergers & Acquisitions
Represented Engage Therapeutics Inc. in its sale to UCB (Euronext Brussels: UCB) for $125 million in upfront cash and up to $145 million in further potential milestone payments related to the clinical development, submission, and launch of Staccato® Alprazolam
Represented Amneal Pharmaceuticals Inc. (NYSE: AMRX) in its acquisition of a 65.1% majority interest in federal healthcare company AvKARE and its related affiliate doing business as R&S Northeast, a transaction valued at $340 million
Represented Humanwell Healthcare Group and PuraCap Pharmaceutical LLC in their acquisition of Epic Pharma of Laurelton, New York for $550 million
Represented Quantum Global Technologies LLC in its sale to Ultra Clean Holdings, Inc. (NASDAQ: UCTT) for approximately $342 million
Represented Marketeching Solutions, a leading research and social listening company, in its sale to W2O Group and its private equity sponsor Mountaingate Capital
Temple University Beasley School of Law, 2016, J.D., cum laude
Georgetown University, 2011, B.A.
Awards and Affiliations
Berkeley Law and the National Venture Capital Association's VC University Online, February 2021 Cohort